$AMYT News

Last published 2y ago

2y agoAMYTApproval of Filsuvez, Nda #215064 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 12/18/2023; Drug Name: Filsuvez, Nda #215064; Active Ingredients: BIRCH TRITERPENES; Company: Amryt; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 215064
3y agoAMYTChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma PlcPR Newswire● Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023
3y agoAMYTChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma PlcGlobeNewswireChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare
3y agoAMYT2022 for Chiesi: The Group's international growth continuesGlobeNewswireTurnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area is as follows: Air
3y agoAMYTHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementGlobeNewswireHigh Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt")
3y agoAMYTAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiGlobeNewswireAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global,
3y agoAMYTAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023GlobeNewswireAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 Dublin, Ireland, February 16, 2023 Amryt Pharma Plc ("Amryt")
3y agoAMYTAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHGlobeNewswireAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company
3y agoAMYTCOMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine TumorsGlobeNewswireCOMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN, Ireland, and Boston MA, December 19, 2022 Amryt (NASDAQ:AMYT),
3y agoAMYTEuropean Commission approves Mycapssa® for the treatment of AcromegalyGlobeNewswireEuropean Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial DUBLIN,
3y agoAMYTAmryt Announces New Patent for Mycapssa®GlobeNewswireAmryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and
4y agoAMYT CHMAAmryt Reports Q3 2022 Financial and Operational ResultsGlobeNewswireAmryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating
4y agoAMYTAmryt Supports Acromegaly Awareness Day 2022GlobeNewswireAmryt Supports Acromegaly Awareness Day 2022 DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (NASDAQ:AMYT, AIM: AMYT)), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and
4y agoAMYTThe British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis BullosaGlobeNewswireThe British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage
4y agoAMYTAmryt Supports Global EB Awareness Week 2022GlobeNewswireAmryt Supports Global EB Awareness Week 2022 DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (NASDAQ:AMYT, AIM: AMYT)), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing
4y agoAMYTAmryt to Report Q3 2022 Results on November 3, 2022GlobeNewswireAmryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and
4y agoAMYTCOMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of AcromegalyGlobeNewswireCOMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage
4y agoAMYTAmryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)GlobeNewswireAmryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, October 17, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage
4y agoAMYTAmryt Supports FH Awareness Day – September 24, 2022GlobeNewswireAmryt Supports FH Awareness Day – September 24, 2022 DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT))), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing no
4y agoAMYTCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalyGlobeNewswireCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly Positive opinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 16, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical c
4y agoAMYTAmryt Announces New Patent for Mycapssa®GlobeNewswireAmryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare
4y agoAMYTAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainGlobeNewswireAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN, Ireland, and Boston MA, September 8, 2022, Amryt
4y agoAMYTAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022GlobeNewswireAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, develop
4y agoAMYT CHMAAmryt Reports Record Q2 2022 ResultsGlobeNewswireAmryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in
4y agoAMYTAmryt to Report Q2 2022 Results on August 4, 2022GlobeNewswireDUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financia
4y agoAMYTAmryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid SyndromeGlobeNewswireAmryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focus
4y agoAMYTAmryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022GlobeNewswireAmryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on procedural pain and dressing change frequency, and
4y agoAMYTResults of Annual General MeetingGlobeNewswireDUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions
4y agoAMYTAmryt Announces Appointment of Dr Tracy Cunningham as Chief Medical OfficerGlobeNewswireAmryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing
4y agoAMYTAmryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDAGlobeNewswireAmryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stag
4y agoAMYTEuropean Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EBGlobeNewswireEuropean Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (NASDAQ:AMYT), a global, com
4y agoAMYTAmryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022GlobeNewswireAmryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety a
4y agoAMYTAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022GlobeNewswireAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 DUBLIN, Ireland, and Boston MA, June 8, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company d
4y agoAMYTPosting of Annual Report and Notice of AGMGlobeNewswirePosting of Annual Report and Notice of AGM DUBLIN, Ireland, and Boston MA, June 1, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare disease
4y agoAMYTAmryt Announces Details of EMA Contingent Value Rights PaymentGlobeNewswireAmryt Announces Details of EMA Contingent Value Rights Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatme
4y agoAMYTAmryt Announces New Patent for Mycapssa®GlobeNewswireAmryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, May 11, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases
4y agoAMYT CHMAAmryt Reports Record Q1 2022 ResultsGlobeNewswireAmryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurc
4y agoAMYTCHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EBGlobeNewswireCHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB Filsuvez® would be the first and only approved treatme
4y agoAMYTAmryt to Report Q1 2022 Results on May 4, 2022GlobeNewswireAmryt to Report Q1 2022 Results on May 4, 2022 DUBLIN, Ireland, and Boston MA, April 14, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare di
4y agoAMYTAmryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly PatientsGlobeNewswireAmryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients were exposed to Mycapssa® during the OPTIMAL Phase
4y agoAMYTAmryt Supports World Lipodystrophy Day - March 31, 2022GlobeNewswireAmryt Supports World Lipodystrophy Day - March 31, 2022 DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatme
4y agoAMYTAmryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EBGlobeNewswireAmryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation at the American Academy of Dermatology Annual meeting 2022 Body surface area percentage of partial thickn
4y agoAMYT CHMAAmryt Announces 22% growth in FY 2021 Revenues to $222.5MGlobeNewswireAmryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th con
4y agoAMYTAmryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)GlobeNewswireAmryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules) Data supports a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET) Global NET market opportunity is estimate
4y agoAMYTKirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Amryt Pharma plc (AMYT) InvestorsBusiness WireThe law firm of Kirby McInerney LLP is investigating potential claims against Amryt Pharma plc ("Amryt Pharma" or the "Company") (NASDAQ:AMYT). The investigation concerns whether Amryt Pharma has violated the federal securities laws and/or engaged in ot
4y agoAMYTResults of General MeetingGlobeNewswireResults of General Meeting Share-Repurchase Program Form of Contract and Counterparties Approved DUBLIN, Ireland, and Boston MA, March 3, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, develo
4y agoAMYTAmryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDAGlobeNewswireAmryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializi
4y agoAMYTAmryt Supports Rare Disease Day 2022GlobeNewswireAmryt Supports Rare Disease Day 2022 DUBLIN, Ireland, and Boston MA, February 25, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases,
4y agoAMYTAmryt to Report FY and Q4 2021 Results on March 9, 2022GlobeNewswireAmryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatm
4y agoAMYT ARESAmryt Completes $125 Million Non-Dilutive Debt RefinancingGlobeNewswireAmryt Completes $125 Million Non-Dilutive Debt Refinancing New Facilities Will Significantly Reduce Amryt's Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027 Further Strengthens Amryt's Balance Sheet and Provides Incre